Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 1999

View Archived Issues

Company Profile: Stanford Rook

Genzyme Tissue Repair: Q1 1999 highlights

Nabi reports preliminary data from Nabi-Altastaph trial in neonates

LeuTech effective in diagnosis of appendicitis

Aronex initiates Annamycin leukemia trial

Positive preclinical results for Avant's complement inhibitor

Carter-Wallace to distribute Calypte Biomedical's HIV diagnostics in U.S.

Micrologix completes phase I trial for prevention of bloodstream infections

Company Profile: Cytovia

Company Profile: Epimmune

Medco: Q1 1999 highlights

Bone Care International: Q3 1999 highlights

Orally active fibrinogen antagonist developed by Merck

Merck KGaA designs new agent with good neuroleptic activity, low liability for side effects

Anti-HBV agents in development at Australian research center

Licensing opportunity from NIH: treatment of stroke and neurodegeneration

Inhibitors of factor Xa recently disclosed by DuPont

Duphar's new CRF antagonists and their use for stress-related disorders

Wide-spectrum receptor binding profile for new tetrahydro gamma-carbolines

Allergen patents new thromboxane receptor ligands with particular utility in ocular hypertension

New beta3-agonist characterized in vitro by SB

SCRC-2941-18: new IL-6 inhibitor with potential for osteoporosis

Pivotal results demonstrate equal efficacy and better tolerability of Diacol versus NuLYTELY

Intracoronary pyruvate has inotropic activity in patients with CHF

Chiroscience identifies development candidate from PDE4 collaboration with Schering-Plough

Pharmacia & Upjohn introduces new antiparkinsonian in the U.K.

Health Canada expands approved uses of Rebetron

Alizyme selects potential antiobesity product emerging from collaboration

Antiangiogenic cytogenin derivative potentially useful for tumors, arthritis